secwatch.observer — SEC 8-K summary
======================================

Issuer:     Perspective Therapeutics, Inc. (CATX)
CIK:        0000728387
Form:       8-K
Filed at:   2024-04-16T23:59:59+00:00
Accession:  0000950170-24-044769
Event type: m_and_a
Sentiment:  positive
Materiality: 0.65
Item codes: 2.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Perspective Therapeutics closes sale of Isoray Cesium-131 business for stock and royalties
--------------------------------------------------------------------------------

- Sale closed April 12, 2024; Isoray receives 279,516 GT Medical shares (0.5% fully diluted, 0.44% if C-1 warrants exercised) and 4-year tiered royalties.
- Royalty on Cesium-131 seed ex-GammaTile: 3% (≤$10M annual net sales), 4% ($10-15M), 5% (≥$15M); GammaTile royalty: 0.5%.
- Pro forma 2023 continuing ops: revenue $1.5M, net loss $37.0M (vs reported $46.5M net loss including discontinued ops).
- Discontinued Isoray ops 2023: net sales $6.9M, net loss $4.9M plus $4.17M loss on classification as held for sale.
- Pro forma balance sheet: total assets $92.8M, stockholders' equity $75.2M after removing Isoray assets/liabilities.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/728387/000095017024044769/0000950170-24-044769-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/728387/000095017024044769/catx-20240412.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-044769

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer